Coave Therapeutics Secures €32 Million in Series A Funding
Deal News | Jan 13, 2025 | Goodwin
In a significant move for genetic medicine innovation, Coave Therapeutics has secured €32 million in Series A financing. The round was co-led by Novo Holdings A/S and Bpifrance, with contributions from Invus and UI Investissement, alongside existing investors such as Seroba Life Sciences and Kurma Partners. The financing aims to enhance Coave's proprietary ALIGATER platform, which advances genetic delivery to extra-hepatic tissues with improved efficiency and safety. This investment will also support the clinical development of Coave's preclinical assets, focusing on central nervous system, neuromuscular, and eye diseases, with clinical trials for two candidates set for 2026. Goodwin's Paris Technology team, led by Anne-Charlotte Rivière, provided legal advisory services on the investment.
Sectors
- Biotechnology
- Healthcare Investment
Geography
- France – Coave Therapeutics and several investors, including Bpifrance and UI Investissement, are based in France, and Goodwin's Paris Technology team provided advisory.
- Denmark – Novo Holdings A/S, a leading company involved in the co-leading of the investment round, is based in Denmark.
Industry
- Biotechnology – Coave Therapeutics operates in the biotechnology sector, focusing on genetic medicines, specifically targeting central nervous system, neuromuscular, and eye diseases.
- Healthcare Investment – The investment into Coave Therapeutics is a strategic move by private equity firms and investors focused on advancing healthcare innovations.
Financials
- €32 Million – The total amount raised in the Series A financing round by Coave Therapeutics.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Coave Therapeutics | Target company | Company | A biotechnology company specializing in genetic medicines. |
| Novo Holdings A/S | Investor | Company | A leading international life sciences investor. |
| Bpifrance | Investor | Company | French investment bank supporting innovation and growth. |
| Invus | Investor | Company | A global investment firm participating in the funding round. |
| UI Investissement | Investor | Company | A French investment company contributing to the Series A round. |
| Seroba Life Sciences | Existing Investor | Company | An existing investor in the biotechnology and medical sector. |
| Fund+ | Existing Investor | Company | An existing investor supporting life sciences companies. |
| Kurma Partners | Existing Investor | Company | A European venture capital company focused on healthcare. |
| Omnes Capital | Existing Investor | Company | A strategic investment partner in private equity markets. |
| Turenne Capital | Existing Investor | Company | A French firm investing in innovative growth companies. |
| Goodwin | Legal Advisor | Company | Provided legal advisory services for the transaction, based in Paris. |
| Anne-Charlotte Rivière | Lead Advisor | Person | Led the Goodwin team advising on the investment. |